Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631371 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 791
- Enrollment target
NCT00631371 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 791 participants.
The verdict
NCT00631371, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 791 participants
- Enrollment target
Study Summary
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.
Interventions
- DRUG Bevacizumab
- DRUG Temsirolimus
- DRUG Interferon-Alfa 9MU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 791 participants |
| Start Date | 2008-04 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631371
The ClinicalTrials.gov registry entry for NCT00631371 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 791 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00631371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631371 about?
NCT00631371 is a clinical study titled "Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects". Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed),...
What is the current status of trial NCT00631371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 791 participants. The study started on 2008-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00631371?
The interventions under investigation include: Bevacizumab (DRUG), Temsirolimus (DRUG), Interferon-Alfa 9MU (DRUG).
Who is sponsoring clinical trial NCT00631371?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.